Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

MLA

Kennedy, Vanessa E., et al. “Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 2244–46. EBSCOhost, https://doi.org/10.1182/blood-2022-160304.

APA

Kennedy, V. E., Peretz, C., Lee, P., Chyla, B., Sun, Y., Dail, M., Hill, J., Tran, E., Koh, A., Altman, J. K., Daver, N., Levis, M. J., McCloskey, J., Perl, A., & Smith, C. (2022). Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax. Blood, 140(1, Number 1 Supplement 1), 2244–2246. https://doi.org/10.1182/blood-2022-160304

Chicago

Kennedy, Vanessa E., Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, et al. 2022. “Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax.” Blood 140 (1, Number 1 Supplement 1): 2244–46. doi:10.1182/blood-2022-160304.